CMTA Strategy to Accelerate Research (CMTA-STAR) Alliance Partner Vanda Pharmaceuticals has announced that the U.S. Food...
CMTA research takes the stage at PNS
PNS 2026 showcased CMTA's role in advancing CMT research across the translational pipeline, from biomarkers and natural history studies to clinical trials, therapeutic development, and the scientific collaborations driving progress.
What Filspari Means for People with CMTDIE
FDA approval of Filspari creates a new treatment option for FSGS that may benefit some people living with CMTDIE. Learn why this milestone matters.
CMTA Expands Preclinical Toolbox with New CMT1A Assay
CMTA expands its Preclinical Toolbox with a new CMT1A assay, providing researchers with a human-relevant platform to evaluate potential therapies earlier in drug development.
CMTA Appoints Aimee Yrlas Simpson as Chief Revenue Officer, Expanding Its Impact for People Living with CMT
CMTA appoints Aimee Yrlas Simpson as Chief Revenue Officer, bringing more than 25 years of nonprofit leadership experience to help advance research and support people living with CMT.
Geneticist Behind the First Identified Cause of CMT Joins CMTA-STAR Scientific Advisory Board
Vincent Timmerman, PhD, the Belgian geneticist whose lab identified the first known genetic cause of Charcot-Marie-Tooth disease, joins the CMTA-STAR Scientific Advisory Board. Timmerman brings three decades of CMT genetics research and iPSC disease modeling expertise to CMTA's push to advance therapies into clinical trials.
How CMTA Investments Led to Nearly $20 Million in Government Grants for CMT Research
CMTA’s investment of $1.15 million advanced three CMT research programs by providing scientists with the resources to test their ideas.
CMTA Receives Highly Competitive $154,000 American Camp Association Grant for Its Camp Footprint Program
CMTA has received a $154,000 American Camp Association Character at Camp Implementation Grant to launch the Footprint Fellowship: Bringing Camp Magic Home. The two-year initiative extends the Camp Footprint experience beyond summer for 35 inaugural Fellows and positions the program as a national model for character-driven camp programming.
Making Sense of CMT: What New Research Reveals About Variability
CMT looks different from person to person, even within the same family. A newly published review by CMTA-STAR Advisory Board members and leading CMT experts brings together what is currently known about CMT variability, genetics, and disease mechanisms into a single, organized reference.
CMTA-STAR Preclinical Toolbox: A Validated Human iPSC Motor Neuron Assay for CMT2A Now Available
CMTA has developed and validated a human iPSC-derived motor neuron assay for CMT2A in collaboration with ANANDA Devices and BrainXell. Now available through the CMTA-STAR Preclinical Toolbox, the platform enables parallel drug screening and direct visualization of mitochondrial mobility impairment in CMT2A patient-derived neurons.
